Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 19/20 | 0.58 |
| ▸ | NOS2 | P35228 | 6/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11766609 | 0.88 | HTR3E (0.58) | NOS1NOS2HTR3EHTR3BHTR3A | |
| SCHEMBL17254179 | 0.86 | SIGMAR1 (0.54) | NOS1NOS2 | |
| SCHEMBL1933033 | 0.86 | NOS1 (0.51) | NOS1NOS2NOS3 | |
| SCHEMBL17053450 | 0.84 | NOS1 (0.56) | NOS1NOS2HTR3EHTR3BHTR3A | |
| SCHEMBL15947208 | 0.84 | NOS1 (0.56) | NOS1NOS2HTR3EHTR3BHTR3A | |
| SCHEMBL17822043 | 0.84 | NOS1 (0.56) | NOS1NOS2HTR3EHTR3BHTR3A | |
| SCHEMBL15947209 | 0.83 | NOS1 (0.47) | NOS1NOS2NOS3 | |
| SCHEMBL10432239 | 0.82 | NOS1 (0.53) | NOS1NOS2 | |
| SCHEMBL714543 | 0.75 | NOS1 (0.68) | NOS1NOS2HTR3EHTR3BHTR3A | |
| SCHEMBL13613942 | 0.71 | SIGMAR1 (0.44) | NOS1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8080626-B2 | Chain extenders | ALBEMARLE CORPORATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-7964695-B2 | Chain extenders | ALBEMARLE CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110137005-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2078048-A1 | DIAMINE CHAIN EXTENDER COMPOSITIONS | Albemarle Corporation (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080194788-A1 | Diimines and Secondary Diamines | ALBEMARLE CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039571-A1 | DIAMINE CHAIN EXTENDER COMPOSITIONS | ALBEMARLE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070270566-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | NOS1 1070/4885NOS2 366/4885HTR3E 1105/4885 |
| US-20070270566-A1 | Chain Extenders | DDC, PARG, ODC1 | NOS1 2884/4885NOS2 1696/4885HTR3E 2597/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | NOS1 1070/4885NOS2 366/4885HTR3E 1105/4885 |
| US-20080194788-A1 | Diimines and Secondary Diamines | DDT, DDC, AOC1 | NOS1 1286/4885NOS2 586/4885HTR3E 1258/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | NOS1 1070/4885NOS2 366/4885HTR3E 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.